Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980307 | 0.72 | EDNRB (0.39) | SMN1; SMN2ALDH1A1HPGDRAB9AMAOB | |
| SCHEMBL15835950 | 0.56 | MAPT (0.63) | SMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL15835969 | 0.56 | MAPT (0.63) | SMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL2039941 | 0.56 | MAPT (0.63) | SMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL10478418 | 0.56 | MAPT (0.63) | SMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL23085112 | 0.55 | CYP1A2 (0.55) | SMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL26311700 | 0.55 | MAPT (0.61) | SMN1; SMN2ALDH1A1HPGDRAB9ACHEK2 | |
| SCHEMBL20706697 | 0.55 | MAPT (0.61) | SMN1; SMN2ALDH1A1HPGDRAB9ACHEK2 | |
| SCHEMBL24171975 | 0.55 | MAPT (0.61) | SMN1; SMN2ALDH1A1HPGDRAB9ACHEK2 | |
| SCHEMBL15501770 | 0.54 | MAPT (0.55) | SMN1; SMN2ALDH1A1HPGDRAB9ACHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917248-B1 | 1-ACYLDIHYDROPYRAZOL DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-08-19 | — | — | EP | claimed |
| US-7875644-B2 | tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas | MERCK PATENT GMBH (DE) | 2011-01-25 | — | — | US | claimed |
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-09 | — | — | US | claimed |
| EP-1917248-B1 | 1-ACYLDIHYDROPYRAZOL DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MET, FLT3, ERBB3 | SMN1; SMN2 4245/4885ALDH1A1 399/4885HPGD 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.